Zimmer Biomet presented commentary at a competitor conference stating an unexpected revenue growth headwind related to ERP issues, which puts revenue and earnings achievability at risk, Truist tells investors in a research note. The firm, which made no change to its Hold rating and $117 price target, says the update was an “unwelcome negative” one and a step-back from guidance against the backdrop of investors questioning the achievability of the 2024 guidance ever since it was issued.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer news to erase some of recent rally, says Citi
- Zimmer Biomet’s ERP issue likely to pressure sales, EPS estimates, says Stifel
- Zimmer Biomet sees ERP implementation impacting FY24 sales by about 1%
- Unusually active option classes on open September 5th
- Evercore estimates 15c EPS impact from Zimmer Biomet sales warning